C12N 2799/021
For the expression of a heterologous nucleic acid
Official title: for the expression of a heterologous nucleic acid
C12N2799/021 (For the expression of a heterologous nucleic acid) appears on 2,482 US grants and 3,563 published applications in this corpus.
Search patents in C12N- Granted patents
- 2,482
- Published applications
- 3,563
- Assignees
- 1,069
- Inventors
- 4,545
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 9 | 0 |
| 1996 | 17 | 0 |
| 1997 | 52 | 0 |
| 1998 | 112 | 0 |
| 1999 | 128 | 0 |
| 2000 | 129 | 0 |
| 2001 | 106 | 31 |
| 2002 | 154 | 323 |
| 2003 | 136 | 1105 |
| 2004 | 118 | 295 |
| 2005 | 122 | 275 |
| 2006 | 149 | 168 |
| 2007 | 191 | 170 |
| 2008 | 192 | 152 |
| 2009 | 124 | 167 |
| 2010 | 109 | 152 |
| 2011 | 90 | 122 |
| 2012 | 88 | 99 |
| 2013 | 68 | 90 |
| 2014 | 54 | 70 |
| 2015 | 52 | 53 |
| 2016 | 54 | 58 |
| 2017 | 47 | 61 |
| 2018 | 41 | 31 |
| 2019 | 24 | 37 |
| 2020 | 25 | 31 |
| 2021 | 22 | 20 |
| 2022 | 14 | 14 |
| 2023 | 14 | 12 |
| 2024 | 14 | 14 |
| 2025 | 15 | 9 |
| 2026 | 8 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2799/026Where the vector is derived from a baculovirusIndexing code986
- C12N 2799/027Where the vector is derived from a retrovirusIndexing code480
- C12N 2799/022Where the vector is derived from an adenovirusIndexing code478
- C12N 2799/025Where the vector is derived from a parvovirusIndexing code163
- C12N 2799/023Where the vector is derived from a poxvirusIndexing code146
- C12N 2799/028Where the vector is derived from a herpesvirusIndexing code63
Recent patents
- Gene-therapy vectors for treating cardiomyopathy29 Sep 2026US 12,747,453 B2
- Gene-therapy vectors for treating cardiomyopathy22 Sep 2026US 12,742,181 B2
- Baculovirus expression vector4 Aug 2026US 12,697,381 B2Intervet Inc.
- Immunomodulating gene therapy26 May 2026US 12,636,302 B2Duke University
- HLA class II deficient cells, HLA class I deficient cells capable of expressing HLA class II proteins, and uses thereof26 May 2026US 12,636,354 B2University of Washington through its Center for Commercialization
- Hla class ii deficient cells, hla class i deficient cells capable of expressing hla class ii proteins, and uses thereof3 Sep 2026US 2026/0256896 A1University of Washington through its Center for Commercialization
- Further improved aav vectors produced in insect cells23 Jul 2026US 2026/0209798 A1uniQure IP B.V.
- Combination cancer therapy14 May 2026US 2026/0131028 A1Delta Next-Gene, LLC
- 3d cell culture methods5 Feb 2026US 2026/0035661 A1Fondazione Telethon Ets (50%)
- Rna engineered t cells for the treatment of cancer6 Nov 2025US 2025/0340869 A1The Trustees of the University of Pennsylvania
Most cited
By later US patents
- Polypeptide variants with altered effector function1,378US 6,737,056 B1Genentech, Inc. · 2004
- Inhibition of cell proliferation using antisense oligonucleotides753US 5,756,476 AThe United States of America as represented by the Department of Health and Human Services · 1998
- Polypeptide variants with altered effector function381US 7,371,826 B2Genentech, Inc. · 2008
- Polypeptide variants with altered effector function373US 7,332,581 B2Genentech, Inc. · 2008
- Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma287US 5,776,456 AIDEC Pharmaceuticals Corporation · 1998